Anzeige
Mehr »
Login
Donnerstag, 14.11.2024 Börsentäglich über 12.000 News von 676 internationalen Medien
Kolumbiens nächster Kupferriese? Warum Investoren dieses 14.000-Meter-Bohrprogramm beobachten!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A1J6DY | ISIN: CA0906901081 | Ticker-Symbol:
Branche
Pharma
Aktienmarkt
Sonstige
1-Jahres-Chart
BIOSYENT INC Chart 1 Jahr
5-Tage-Chart
BIOSYENT INC 5-Tage-Chart
GlobeNewswire (Europe)
314 Leser
Artikel bewerten:
(2)

BioSyent Inc.: BioSyent Releases Financial Results for Q1 2024

Finanznachrichten News

MISSISSAUGA, Ontario, May 16, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", TSX Venture: RX) released today its financial results for the three months (Q1) ended March 31, 2024. Key highlights include:

(CAD)Q1 2024% Change vs.
Q1 2023
Trailing Twelve Months
(TTM)
March 31, 2024
% Change vs.
TTM
March 31, 2023
Canadian Pharma Sales7,546,14418%30,689,34916%
International Pharma Sales-0%1,047,747789%
Total Company Sales7,733,63619%32,841,24420%
EBITDA12,204,19345%8,614,03728%
Net Income After Taxes (NIAT)1,768,72750%7,053,60840%
Fully Diluted EPS0.1550%0.5944%
  • Return on Equity for TTM March 31, 2024 was 21% as compared to 15% for TTM March 31, 2023
  • During Q1 2024, repurchased for cancellation a total of 156,200 common shares under a Normal Course Issuer Bid (NCIB)
  • Paid quarterly cash dividends of $0.045 per common share on March 15, 2024, an increase of 12.5% from the previous quarterly dividend

"Our Canadian pharmaceutical business got off to a fast start in Q1 2024 with 18% revenue growth over the comparative period," said René Goehrum, President and CEO of BioSyent. "All of our Canadian pharmaceutical brands contributed to this growth during the quarter. Our three launch brands, FeraMAX® Pd Maintenance 45, Inofolic®, and Gelclair® also contributed modest incremental growth during Q1 2024. We remain focused on continuing to grow our Canadian pharmaceutical business during the remainder of the year with continued selling and promotional investment in our launch brands. I look forward to reporting on our progress in 2024."

The CEO's presentation on the Q1 2024 Results is available at the following link: www.biosyent.com/investors/

The Company's Interim Unaudited Condensed Consolidated Financial Statements and Management's Discussion and Analysis for the three months ended March 31, 2024 and 2023 will be posted on www.sedarplus.ca on May 16, 2024.

For a direct market quote for the TSX Venture Exchange and other Company financial information, please visit www.tmxmoney.com.

About BioSyent Inc.

Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.

As of the date of this press release, the Company has 11,585,169 common shares outstanding.

BioSyent Inc.
Interim Unaudited Condensed Consolidated Statements of Comprehensive Income
In Canadian DollarsQ1 2024 Q1 2023 % Change
Net Revenues7,733,636 6,482,694 19%
Cost of Goods Sold1,589,762 1,147,962 38%
Gross Profit6,143,874 5,334,732 15%
Operating Expenses and Finance Income/Costs3,737,443 3,735,758 0%
Net Income Before Tax2,406,431 1,598,974 50%
Tax (including Deferred Tax)637,704 423,728 50%
Net Income After Taxes1,768,727 1,175,246 50%
Net Income After Taxes % to Net Revenues23% 18%
EBITDA2,204,193 1,516,634 45%
EBITDA % to Net Revenues29% 23%
  1. EBITDA is a Non-IFRS Financial Measure. The term EBITDA does not have any standardized meaning under International Financial Reporting Standards (IFRS) and therefore may not be comparable to similar measures presented by other companies. The Company defines EBITDA as earnings before interest income or expense, income taxes, depreciation and amortization.

BioSyent Inc.
Interim Unaudited Condensed Consolidated Statements of Financial Position
AS ATMarch 31, 2024December 31, 2023% Change
ASSETS
Cash, cash equivalents and short-term investments$23,687,796$26,187,011-10%
Trade and other receivables 2,791,794 3,477,096-20%
Inventory 5,718,882 5,894,495-3%
Derivative asset 11,550 -100%
Prepaid expenses and deposits 569,144 243,460134%
Loans receivable - current 73,452 69,4196%
CURRENT ASSETS 32,852,618 35,871,481-8%
Long term investments 4,106,547 2,500,00064%
Loans receivable - non current 205,182 205,1820%
Deferred tax asset 343,607 359,470-4%
Property and equipment 1,373,868 1,439,930-5%
Intangible assets 1,114,612 1,152,876-3%
TOTAL NON CURRENT ASSETS 7,143,816 5,657,45826%
TOTAL ASSETS$39,996,434$41,528,939-4%
LIABILITIES AND SHAREHOLDERS' EQUITY
CURRENT LIABILITIES$4,256,689$5,533,850-23%
NON CURRENT LIABILITIES 1,187,820 1,235,333-4%
Long term debt - -0%
Total Equity 34,551,925 34,759,756-1%
TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY$39,996,434$41,528,939-4%

For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web: www.biosyent.com

This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.


© 2024 GlobeNewswire (Europe)
Nach Nvidia: 5 KI-Revolutionäre aus der zweiten Reihe!
Künstliche Intelligenz hat spätestens nach dem Raketenstart von Chat GPT das Leben aller verändert. Doch der Superzyklus steht nach Meinungen von Experten erst am Anfang. Während Aktien wie Nvidia von der ersten Aufwärtsentwicklung stark profitieren konnten, versprechen aussichtsreiche Player aus der

zweiten Reihe noch enormes Aufwärtspotenzial.

Im kostenlosen, exklusiven Spezialreport präsentieren wir ihnen 5 innovative KI-Unternehmen, die bahnbrechende Entwicklungen in diesem Sektor prägen könnten.

Warum sollten Sie dabei sein?
Trotz der jüngsten Erfolge steht die Entwicklung der künstlichen Intelligenz noch am Beginn eines neuen Superzyklus. Experten gehen davon aus, dass der Sektor bis 2032 global auf 1,3 Billionen US-Dollar explodieren wird, wobei ein großer Teil auf Hardware und Infrastruktur entfallen wird.

Nutzen Sie die Chance!
Fordern Sie sofort unseren brandneuen Spezialreport an und erfahren Sie, welche 5 KI-Aktien das größte Potenzial zur Vervielfachung besitzen. Dieser Report ist komplett kostenlos und zeigt Ihnen die aussichtsreichsten Investments im KI-Sektor.
Handeln Sie jetzt und sichern Sie sich Ihren kostenfreien Report!

Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.